<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dapsone (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dapsone (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dapsone (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9096" href="/d/html/9096.html" rel="external">see "Dapsone (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11647" href="/d/html/11647.html" rel="external">see "Dapsone (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52869101"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>MAR-Dapsone;</li>
<li>RIVA-Dapsone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10483704"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Sulfone</span>;</li>
<li>
<span class="list-set-name">Leprostatic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462653"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd16db98-c243-48e5-8031-c48622e67659">Linear IgA bullous dermatosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Linear IgA bullous dermatosis (LABD):</b> Very limited data available: Term infants: Oral: 0.5 or 1 mg/kg/day; dosing based on experience from two case reports (PNA: 9 days and 20 days) which showed a positive response to dapsone therapy; however, adverse effects hindered treatment course. In the case report involving the youngest patient (PNA: 9 days), the initial dose was 1 mg/kg/day with concurrent prednisolone; the dose was increased to 2 mg/kg/day at which point the neonate developed methemoglobinemia by day 14 of treatment and dapsone was temporarily discontinued; a second course was initiated at 9 months of age for another disease flare at 0.5 mg/kg/day (Gluth 2004). In the other case report (PNA: 20 days), initial therapy was 0.5 mg/kg/day; the dose was later increased to 1 mg/kg/day; while LABD improved on dapsone therapy, the patient developed pneumonia (highly resistant) which required discontinuation of dapsone (Kishida 2004).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F8015320"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9516bf6f-8767-418a-8f45-c42df4ae7711">Dermatitis herpetiformis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatitis herpetiformis:</b> Infants, Children, and Adolescents: Oral: Initial: 0.5 to 2 mg/kg/day in 1 to 2 divided doses (Ermacora 1986; Kliegman 2016); maximum initial daily dose in adults: 50 mg/<b>day</b>; increase dose as needed to achieve control; usual adult dose: 300 mg/dose; once lesions controlled, some have reported that dose may be decreased as tolerated for chronic therapy to a reported range: 0.125 to 0.5 mg/kg/day (Ermacora 1986; Reunala 1984)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="882d0dd9-429d-4c33-87be-da854cc0eadb">Idiopathic thrombocytopenic purpura, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Idiopathic thrombocytopenic purpura (ITP), refractory:</b> Limited data available: Children ≥3 years and Adolescents: Oral: 1 to 2 mg/kg/day for at least 2 months. Dosing based on two retrospective reviews. The first was a retrospective cohort analysis of adult and pediatric (age range: 3 to 61 years, including 35 patients &lt;16 years) with chronic ITP (&gt;6 months with diagnosis) who failed steroid therapy and observed an overall similar response rate for children (65.7%) and adults (Damodar 2005). Adverse effects occurred in three patients (one with acute hemolysis and two with an erythematous rash). The second was a small retrospective report of seven pediatric patients with acute or chronic refractory, symptomatic ITP (age range: 6 to 15 years) which also showed a similar response rate (60%); however, a higher incidence (two of seven patients [29%]) of methemoglobinemia was observed (Meeker 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e8820e5-cd13-4b2d-840c-74174ab30524">Leprosy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy (Hansen's disease): Note:</b> Treatment should be managed in consultation with a leprosy expert; use of multidrug therapy is important to prevent drug resistance (<i>Red Book</i> [AAP 2018]). Recommended duration varies:</p>
<p style="text-indent:-2em;margin-left:4em;">Paucibacillary (Tuberculoid) leprosy (1 to 5 patches):</p>
<p style="text-indent:-2em;margin-left:6em;">National Hansen's Disease Program Recommendations: Infants, Children, and Adolescents: Oral: 1 mg/kg/dose once daily for 12 months; maximum dose: 100 mg/dose; use in combination with rifampin (NHDP [HRSA 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">WHO Recommendations (WHO 2016):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;10 years and weighing &lt;20 kg: Oral: 2 mg/kg/dose once daily for 6 months; use in combination with rifampin</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents ≤14 years:</p>
<p style="text-indent:-2em;margin-left:10em;">20 to 40 kg: Oral: 25 mg once daily for 6 months; use in combination with rifampin</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;40 kg: Oral: 50 mg once daily for 6 months; use in combination with rifampin</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents &gt;14 years: Oral: 100 mg once daily for 6 months; use in combination with rifampin</p>
<p style="text-indent:-2em;margin-left:4em;">Multibacillary (Lepromatous) leprosy (≥6 patches):</p>
<p style="text-indent:-2em;margin-left:6em;">National Hansen's Disease Program Recommendations: Infants, Children, and Adolescents: Oral: 1 mg/kg/dose once daily for 24 months; maximum dose: 100 mg/dose; use in combination with rifampin and clofazimine (NHDP [HRSA 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">WHO Recommendations (WHO 2016):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;10 years and weighing &lt;20 kg: Oral: 2 mg/kg/dose once daily for 12 months; use in combination with rifampin and clofazimine</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents ≤14 years:</p>
<p style="text-indent:-2em;margin-left:10em;">20 to 40 kg: Oral: 25 mg once daily for 12 months; use in combination with rifampin and clofazimine</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;40 kg: Oral: 50 mg once daily for 12 months; use in combination with rifampin and clofazimine</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents &gt;14 years: Oral: 100 mg once daily for 12 months; use in combination with rifampin and clofazimine</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd16db98-c243-48e5-8031-c48622e67659">Linear IgA bullous dermatosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Linear IgA bullous dermatosis (LABD):</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.5 to 2 mg/kg/day in 1 to 2 divided doses with or without prednisone (Kenani 2009; Kliegman 2016; Thappa 2003); may increase if needed at weekly intervals until symptoms controlled; maximum reported daily dose: 4 mg/kg/<b>day</b> (Thappa 2003); usual adult dose: 25 to 150 mg/day (Fortuna 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1ff8bd6-37ed-4d39-b2ab-0bcbbfe8ccc0">
<i>Pneumocystis jirovecii</i> pneumonia, alternative agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis jirovecii</b></i>
<b> pneumonia (PCP), alternative agent (patients unable to take trimethoprim/sulfamethoxazole):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis (primary or secondary): Multiple regimens (daily or weekly dosing) and combinations presented</p>
<p style="text-indent:-2em;margin-left:6em;">
<i> HIV-exposed/-infected: </i>Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: 2 mg/kg/dose once daily (maximum daily dose: 100 mg/<b>day</b>) <b>or</b> 4 mg/kg/dose once <b>weekly</b> (maximum weekly dose: 200 mg/<b>week</b>) (HHS [OI pediatric 2016])</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: 100 mg/day in 1 or 2 divided doses as monotherapy <b>or</b> 50 mg once daily in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg once <b>weekly</b> in combination with weekly pyrimethamine and leucovorin; monotherapy should not be used in patients who are seropositive for <i>Toxoplasma gondii</i> (HHS [OI adult 2018])</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hematopoietic stem cell transplant recipient</i> (CDC/IDSA [Tomblyn 2009]): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: 2 mg/kg/dose once daily; maximum dose: 100 mg/dose</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: 100 mg/day in 1 or 2 divided doses</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment, mild to moderate disease: Limited data available: Infants, Children, and Adolescents (HIV-exposed/-infected): Oral: 2 mg/kg/dose once daily in combination with trimethoprim for 21 days; maximum dose: 100 mg/dose (HHS [OI adult 2018]; HHS [OI pediatric 2016])</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44276aeb-4be9-43c7-881d-416f75f54ad3">
<i>Toxoplasma gondii</i>, primary prophylaxis, HIV-exposed/-infected patients, alternative agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Toxoplasma gondii</b></i>
<b>, primary prophylaxis, HIV-exposed/-infected patients, alternative agent (patients unable to tolerate trimethoprim/sulfamethoxazole):</b>
<b>Note:</b> Multiple regimens (daily or weekly dosing), combinations, and dosing units (mg/kg, mg/<b>m<sup>2</sup></b>) presented; use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 2 mg/kg/dose <b>or</b> 15 mg/<b>m<sup>2</sup></b>/dose once daily in combination with pyrimethamine and leucovorin; maximum dose: 25 mg/dose (HHS [OI pediatric 2016])</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 50 mg once daily in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg once <b>weekly</b> in combination with weekly pyrimethamine and leucovorin (HHS [OI adult 2018])</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090513"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, some clinicians have suggested that no adjustment is necessary (Aronoff 2007).</p></div>
<div class="block dohp drugH1Div" id="F51090514"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F8015321"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9096" href="/d/html/9096.html" rel="external">see "Dapsone (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77f15e51-39e9-4843-ba56-7c8aad22e197">Aphthous ulcers, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aphthous ulcers, severe (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 25 mg daily for 3 days; increase dose in increments of 25 mg daily every 3 days up to 100 mg daily for 3 days, then increase by 25 mg daily every 7 days up to 150 mg daily. Administer in 2 divided doses (75 mg dose is administered in 3 divided doses).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: 100 to 150 mg daily in 2 divided doses with or without concomitant colchicine (Lynde 2009; Rogers 1982).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="144bfda0-cd07-4b30-a02a-f08025a0fc36">Bullous pemphigoid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bullous pemphigoid (alternative agent) (off-label use): Oral:</b> 1 to 1.5 mg/kg/day, with or without immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35766904','lexi-content-ref-19824739','lexi-content-ref-28494097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35766904','lexi-content-ref-19824739','lexi-content-ref-28494097'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18794823-8cbd-4715-8cb8-8f39e63d3c88">Bullous systemic lupus erythematosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bullous systemic lupus erythematosus (off-label use): Oral:</b> 50 mg once daily initially, with or without immunosuppressive therapy; range 25 to 200 mg daily (Contestable 2014; Fabbri 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9516bf6f-8767-418a-8f45-c42df4ae7711">Dermatitis herpetiformis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatitis herpetiformis (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Management involves a combination of a strict lifelong gluten-free diet and drug therapy (Antiga 2015; Salmi 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg daily; may increase as needed to 100 to 200 mg daily to achieve full control. Once rash is controlled, dose may be gradually tapered to a minimum maintenance dosage with eventual discontinuation based on clinical response (Antiga 2015; Salmi 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (alternative agent) (off-label use):</b>
<b>Oral:</b> 50 to 100 mg daily or 1 to 2 mg/kg/day; duration of therapy is ≥21 days (ASH [Neunert 2019]; Damodar 2005; Godeau 1997; Provan 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e8820e5-cd13-4b2d-840c-74174ab30524">Leprosy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy: Oral:</b> 100 mg once daily as part of an appropriate combination regimen for 12 months for tuberculoid (paucibacillary) disease and 24 months for lepromatous (multibacillary) disease (NHDP [HRSA 2018]). <b>Note:</b> For resource-limited settings, the World Health Organization recommends 6 months for tuberculoid and 12 months for lepromatous (WHO 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6ea3bd9-fabe-4630-97e3-9b4f73592607">Pemphigus vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pemphigus vulgaris (adjunctive agent) (off-label use):</b>
<b>Oral:</b> 25 mg daily for 7 days, then increase dose in increments of 25 mg daily every 7 days up to 100 mg daily for 7 days (4 weeks total therapy) with concomitant prednisone. Administer in 2 divided doses (a 75 mg dose is administered in 3 divided doses) (Azizi 2008). Usual dose range: 50 to 200 mg daily (Porro 2019). <b>Note: </b>If patient becomes lesion free, taper and discontinue gradually by decreasing dose 25 mg daily over 7 days. If no new lesions are seen, gradual taper is continued. If lesions recur, dose is increased by 25 mg daily at 7-day intervals until the patient develops no new lesions. Taper is usually ~4 weeks total (Azizi 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b6d76e0-daa4-4f7d-820b-c477162bb88f">
<i>Pneumocystis</i> pneumonia in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis </b></i>
<b>pneumonia in patients with HIV (alternative agent) (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis (primary or secondary):</i> 100 mg once daily or in 2 divided doses as monotherapy <b>or</b> 50 mg daily in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg <b>weekly</b> in combination with weekly pyrimethamine and leucovorin<b>.</b> Continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months in response to antiretroviral therapy (ART); some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3 </sup>who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI Adult 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (mild to moderate disease):</i> 100 mg once daily in combination with trimethoprim for 21 days (HHS [OI Adult 2020]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="399db946-8e39-4223-8f9d-c83ef45d608d">Pyoderma gangrenosum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyoderma gangrenosum (alternative agent) (off-label use): Oral: </b>50 to 200 mg daily (Callen 2007; Din 2018; Vidal 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1357e8cf-d08f-47b1-a325-b9a7d1986cda">Relapsing polychondritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Relapsing polychondritis (off-label use): Oral: </b>25 to 200 mg daily (Damiani 1979; Ridgway 1979).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="033027c3-5965-4e73-838b-539d5eccee2d">
<i>T. gondii</i> encephalitis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>T. gondii</b></i>
<b> encephalitis in patients with HIV (alternative to preferred therapy) (off-label use):</b>
<i>Primary prophylaxis: </i>
<b>Oral:</b> 50 mg daily, in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg <b>weekly</b> in combination with weekly pyrimethamine and leucovorin. Continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months in response to ART; some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI Adult 2020]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990742"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:0em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:0em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (Legendre 2012; expert opinion).</p>
<p style="text-indent:0em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment likely necessary based on pharmacokinetic properties (only 5% to 15% excreted in urine unchanged). However, use with caution and at the lower end of the indication-specific recommended dosing range when possible, with close monitoring of blood counts, as there are reports of dose-dependent hematologic toxicities (eg, methemoglobinemia, hemolysis) in patients with kidney impairment (Abouraya 2012; Lee 2015; Mannemuddhu 2021; Naik 2008; Nessim 2010; Serwin 2002; Tan 2020; Ward 1998; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (moderate V<sub>d</sub>, moderate to high protein binding): Dose as for eGFR &lt;30 mL/minute/1.73 m<sup>2 </sup>(expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (moderate V<sub>d</sub>, moderate to high protein binding): Dose as for eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988112"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (Legendre 2012)</p></div>
<div class="block arsc drugH1Div" id="F56962267"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dapsone is associated with <b>methemoglobinemia</b>, <b>hemolytic anemia</b>, <b>neutropenia</b>, and <b>agranulocytosis</b>. There are rare reports of <b>aplastic anemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7967777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7967777'])">Ref</a></span>) and <b>pancytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35464541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35464541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Methemoglobinemia</b>: Symptoms may be absent or mild and nonspecific (eg, malaise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215452'])">Ref</a></span>), headache, fatigue, tachycardia, (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>) but can be severe with dyspnea, cyanosis, and hypoxia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596','lexi-content-ref-32714715','lexi-content-ref-24215452','lexi-content-ref-35371634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596','lexi-content-ref-32714715','lexi-content-ref-24215452','lexi-content-ref-35371634'])">Ref</a></span>), and it has been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342970'])">Ref</a></span>). Mean peak methemoglobin of 7.6% (range: 2.1% to 34.1%) of hemoglobin has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342970'])">Ref</a></span>). A "saturation gap" between SpO<sub>2</sub>A and SaO<sub>2</sub>, chocolate-brown arterial blood, and cyanosis presenting as pasty brown mucous membranes are considered characteristic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>). Dapsone discontinuation with supplemental oxygen as indicated generally leads to resolution within 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596','lexi-content-ref-32714715','lexi-content-ref-16212642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596','lexi-content-ref-32714715','lexi-content-ref-16212642'])">Ref</a></span>); however, cases have taken longer to resolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596','lexi-content-ref-16212642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596','lexi-content-ref-16212642'])">Ref</a></span>). Reported incidences vary depending on case definitions: Cyanosis or hypoxia (O<sub>2</sub> saturation ≤95%) with methemoglobin level ≥3% occurred in 20% of those taking dapsone in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21246536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21246536'])">Ref</a></span>). Methemoglobin levels &gt;1.5% occurred 46% in another study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215452'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemolytic anemia</b>: Dapsone-induced hemolytic anemia may be found on routine monitoring or after presentation with mild symptoms (eg, fatigue, exertional dyspnea) in those without G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32947344','lexi-content-ref-32753123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32947344','lexi-content-ref-32753123'])">Ref</a></span>). Patients with G6PD deficiency present with more severe symptoms (eg, tachycardia, tachypnea, mild hypoxia in room air) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27230975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27230975'])">Ref</a></span>). <b>Decreased hemoglobin</b> has been reported in patients without G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32947344','lexi-content-ref-25628986','lexi-content-ref-32047930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32947344','lexi-content-ref-25628986','lexi-content-ref-32047930'])">Ref</a></span>); however, patients with G6PD deficiency experience more significant reductions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27230975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27230975'])">Ref</a></span>)). Hemolytic anemia has been fatal in resource limited settings despite transfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721106'])">Ref</a></span>). Recovery usually occurs 8 to 10 days after discontinuation but has taken up to ~3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29305344','lexi-content-ref-32947344','lexi-content-ref-32753123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29305344','lexi-content-ref-32947344','lexi-content-ref-32753123'])">Ref</a></span>). Up to 10% may require packed red cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29305344','lexi-content-ref-27230975','lexi-content-ref-22993389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29305344','lexi-content-ref-27230975','lexi-content-ref-22993389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neutropenia</b>: Neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>) can be severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35464541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35464541'])">Ref</a></span>) and has been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>). ANC generally recovers ≤1 month after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Agranulocytosis</b>: Approximately 90% of cases present with fever and other symptoms of infection while the remainder are detected on routine CBC monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33270224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33270224'])">Ref</a></span>). Absolute neutrophil counts as low as 0 cells/mm<sup>3</sup> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198424'])">Ref</a></span>) and has been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470834'])">Ref</a></span>). Neutrophils normalize a median of 10 days after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470834','lexi-content-ref-32140985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470834','lexi-content-ref-32140985'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Methemoglobinemia</b>: Dose-related; hydroxylamine metabolite oxidizes ferrous iron (Fe2+) in heme to ferric iron (Fe3+), converting hemoglobin to methemoglobin which has reduced oxygen carrying capacity. NADH dependent cytochrome b5 reductase, NADPH-dependent methemoglobin reductase, ascorbic acid, and glutathione mediated removal of methemoglobin are overwhelmed and the proportion of methemoglobin to hemoglobin is increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemolytic anemia</b>: Dose-related; hydroxylamine metabolite and nitroso-dapsone, formed during conversion of hemoglobin to methemoglobin, generate reactive oxygen radicals. In G6PD deficiency, these accumulate and directly damage red blood cell membranes leading to hemolysis. The hydroxylamine metabolite can directly affect phosphorylation of membrane proteins, leading to hemolysis in those without G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Neutropenia and Agranulocytosis</b>: Non–dose-related; hydroxylamine is toxic to bone marrow myeloid cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244','lexi-content-ref-3129552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244','lexi-content-ref-3129552'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Methemoglobinemia</b>: Varied; ranges from 1 day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993389'])">Ref</a></span>) to 5 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24215452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24215452'])">Ref</a></span>) or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21246536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21246536'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemolytic anemia</b>: Varied; presenting within 24 to 72 hours then worsening until days 7 to 8 in individuals with G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29305344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29305344'])">Ref</a></span>). May present later in individuals without G6PD deficiency with reports ranging from 11 to 71 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32947344','lexi-content-ref-30030892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32947344','lexi-content-ref-30030892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Neutropenia</b>: Varied; typical time to onset ≤7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Agranulocytosis</b>: Varied; median duration of dapsone treatment before symptom development was 56 days (range: 6 to 133 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33270224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33270224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Methemoglobinemia</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">• More common with higher doses (eg, overdose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21246536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21246536'])">Ref</a></span>), but has been reported with treatment and prophylactic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596','lexi-content-ref-21246536','lexi-content-ref-24215452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596','lexi-content-ref-21246536','lexi-content-ref-24215452'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596','lexi-content-ref-33417185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596','lexi-content-ref-33417185'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mixed evidence for low cytochrome b5 reductase (Cb5R) levels or heterozygosity for Cb5R deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21422237','lexi-content-ref-21246536','lexi-content-ref-15390276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21422237','lexi-content-ref-21246536','lexi-content-ref-15390276'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993389'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent methemoglobinemia-inducing agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• For symptoms:</p>
<p style="text-indent:-2em;margin-left:10em;">- Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Lung disease or pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21852596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21852596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342970'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Abnormal hemoglobin species (eg, carboxyhemoglobin, sulfhemoglobin, or sickle hemoglobin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342970'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemolytic anemia</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">• Dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25628986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25628986'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• G6PD deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29305344','lexi-content-ref-19112496','lexi-content-ref-27230975','lexi-content-ref-22993389','lexi-content-ref-26599634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29305344','lexi-content-ref-19112496','lexi-content-ref-27230975','lexi-content-ref-22993389','lexi-content-ref-26599634'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low ideal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18971091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18971091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25628986','lexi-content-ref-18971091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25628986','lexi-content-ref-18971091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Compromised bone marrow (eg, hematopoietic stem cell transplantation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21478917','lexi-content-ref-30030892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21478917','lexi-content-ref-30030892'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemoglobin H disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11844995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11844995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Neutropenia</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Underlying disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Agranulocytosis</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (&gt;60 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11311458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11311458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Non-Caucasian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11311458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11311458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting severe inflammatory conditions (eg, dermatitis herpetiformis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11311458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11311458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• N-acetyltransferase deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691244'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatic injury ranges from mild <b>increased serum transaminases </b>to fulminant<b> hepatic failure</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16639690','lexi-content-ref-29222960','lexi-content-ref-25156688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16639690','lexi-content-ref-29222960','lexi-content-ref-25156688'])">Ref</a></span>). <b>Hyperbilirubinemia</b> may occur more frequently in G6PD deficient patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993389'])">Ref</a></span>). Hepatotoxicity is most often associated with signs of hypersensitivity, as part of <b>drug rash with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7973902','lexi-content-ref-28552804','lexi-content-ref-35176506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7973902','lexi-content-ref-28552804','lexi-content-ref-35176506'])">Ref</a></span>). Liver injury is typically cholestatic or mixed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28552804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28552804'])">Ref</a></span>). Most cases resolve within 2 to 8 weeks of discontinuing dapsone; although, severe cholestatic injury may be prolonged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25156688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25156688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown: Non–dose-related; possibly hypersensitivity mechanism, through metabolism to a reactive, toxic metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28552804','lexi-content-ref-31631707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28552804','lexi-content-ref-31631707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; duration of therapy prior to onset of hepatotoxicity is typically within a few days to weeks; although, can be delayed up to 5 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28552804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28552804'])">Ref</a></span>). A shorter onset occurs upon rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28552804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28552804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-B*13:01 has been associated with hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427944'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug rash with eosinophilia and systemic symptoms (</b>DRESS; previously known as dapsone or sulfone syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20713773','lexi-content-ref-32961314','lexi-content-ref-22307940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20713773','lexi-content-ref-32961314','lexi-content-ref-22307940'])">Ref</a></span>) has been reported. In most cases, predominant hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22307940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22307940'])">Ref</a></span>) is noted, although <b>pancreatitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25097293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25097293'])">Ref</a></span>), <b>acute kidney injury</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29515281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29515281'])">Ref</a></span>), or <b>eosinophilic pneumonitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832951'])">Ref</a></span>) may also occur. <b>Fever</b>, along with other cutaneous reactions may be reported, including <b>fixed drug eruption</b>, photosensitivity, <b>maculopapular rash</b>, and erythematous plaques (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18811870','lexi-content-ref-16756657','lexi-content-ref-26120067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18811870','lexi-content-ref-16756657','lexi-content-ref-26120067'])">Ref</a></span>). Additional serious cutaneous adverse reactions (SCARs) include <b>Stevens-Johnson syndrome/toxic epidermal necrolysis </b>(SJS/TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8038322','lexi-content-ref-28885988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8038322','lexi-content-ref-28885988'])">Ref</a></span>) and <b>acute generalized exanthematous pustulosis</b> (AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24026795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24026795'])">Ref</a></span>). Following discontinuation of dapsone, resolution occurs within days to several months (mean: 27 days); although, may result in fatality in 10% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22307940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22307940'])">Ref</a></span>). In some patients, hypothyroidism and/or diabetes mellitus may develop months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29515281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29515281'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Delayed hypersensitivity reactions: Non–dose-related, immunologic. Delayed hypersensitivity reactions are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. Serious cutaneous adverse reactions, usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>). A mean of a ~32 days has been reported with dapsone but may also occur up to 6 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16756657','lexi-content-ref-22307940','lexi-content-ref-34017337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16756657','lexi-content-ref-22307940','lexi-content-ref-34017337'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-B*13:01 has been associated with SCARs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29512326','lexi-content-ref-30916737','lexi-content-ref-32700588','lexi-content-ref-34017337','lexi-content-ref-29541744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29512326','lexi-content-ref-30916737','lexi-content-ref-32700588','lexi-content-ref-34017337','lexi-content-ref-29541744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity may occur in patients with a history of a hypersensitivity reaction to sulfonamide antibiotics (eg, sulfamethoxazole/trimethoprim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9692656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9692656'])">Ref</a></span>), although dapsone may be considered as an option in patients with mild reactions to sulfonamide antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8678080','lexi-content-ref-9692656','lexi-content-ref-28034550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8678080','lexi-content-ref-9692656','lexi-content-ref-28034550'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients may be at an increased risk for development of DRESS; older patients have decreased production of toxic metabolites due to decreased enzyme activity associated with aging (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16361748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16361748'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8015297"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, hypoalbuminemia (without proteinuria)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Male infertility</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Reticulocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infectious mononucleosis (infectious mononucleosis-like syndrome)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, insomnia, psychomotor impairment, psychosis, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotic syndrome, renal papillary necrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Vas 2013), fixed drug eruption (Sauvetre 2015), maculopapular rash (Kosseifi 2006), phototoxicity (Kar 2008), Stevens-Johnson syndrome (Tempark 2017), toxic epidermal necrolysis (Tempark 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Das 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (St Clair 2021), aplastic anemia (Meyerson 1994), decreased hemoglobin (Khatri 2020, Murphy 2016), hemolysis (Khatri 2020, Murphy 2016), hemolytic anemia (Khatri 2020, Murphy 2016), methemoglobinemia (Shenouda 2022), neutropenia (Hsieh 2020), pancytopenia (Abdur Raheem 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic failure (Devarbhavi 2018), hepatitis (Devarbhavi 2018), hyperbilirubinemia (Pamba 2012), increased serum transaminases (Abidi 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Kang 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Waldinger 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Pai 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Kinehara 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Kosseifi 2006)</p></div>
<div class="block coi drugH1Div" id="F8015294"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dapsone or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Advanced amyloidosis of the kidneys.</p></div>
<div class="block war drugH1Div" id="F8015295"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Use with caution in patients with severe anemia; treat prior to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Dapsone may artificially lower HbA<sub>1c</sub> by reducing erythrocyte survival time through hemolysis (Lai 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Leprosy: New or severe dermatological reactions require discontinuation of therapy; however, leprosy reactional states (eg, erythema nodosum leprosum) do not require discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use with caution in patients with G6PD deficiency; dose-related hemolysis and methemoglobinemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemoglobin M deficiency: Use with caution in patients with hemoglobin M deficiency; dose-related hemolysis may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobin reductase deficiency: Use with caution in patients with methemoglobin reductase deficiency; dose-related hemolysis may occur.</p></div>
<div class="block foc drugH1Div" id="F8015379"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F9490508"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322077"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Dapsone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.47 - $4.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.02 - $4.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869102"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block exp drugH1Div" id="F8015382"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;margin-top:2em;display:inline">A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet® and Ora-Plus®. Crush eight 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label "shake well". Stable for 90 days at room temperature or refrigerated.</p>
<p style="text-indent:0em;margin-top:2em;">Jacobus Pharmaceutical Company makes a 2 mg/mL proprietary liquid formulation available under an IND for the prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia.</p>
<div class="reference">Nahata MC, Morosco RS, and Trowbridge JM, "Stability of Dapsone in Two Oral Liquid Dosage Forms," <i>Ann Pharmacother</i>, 2000, 34(7-8):848-50.<span class="pubmed-id">10928393</span></div>
</div>
<div class="block admp drugH1Div" id="F52614333"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with meals if GI upset occurs.</p></div>
<div class="block adm drugH1Div" id="F8015365"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Oral: Administer with meals if GI upset occurs.</p></div>
<div class="block sts drugH1Div" id="F8015308"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 76°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53570471"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of leprosy due to susceptible strains (FDA approved in pediatric patients [age not specified] and adults); treatment of dermatitis herpetiformis (FDA approved in pediatric patients [age not specified] and adults); has also been used for prophylaxis and treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP); prophylaxis against toxoplasmic encephalitis; treatment of linear IgA bullous dermatosis (LABD); and refractory idiopathic thrombocytopenia purpura (ITP)</p></div>
<div class="block mst drugH1Div" id="F8015264"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dapsone may be confused with Diprosone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8015301"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8015302"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Dapsone (Systemic) may enhance the adverse/toxic effect of Atazanavir. Specifically, the risk of hyperbilirubinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): Dapsone (Systemic) may enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Dapsone (Systemic) may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of dapsone and methotrexate if possible. If coadministration is required, monitor closely for methotrexate toxicities (eg, hematological, gastrointestinal, nephrotoxicity toxicities).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54958007"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In uncontrolled studies and published surveys, dapsone did not affect female reproduction. Male infertility is noted as an adverse event in the dapsone product labeling.</p></div>
<div class="block pri drugH1Div" id="F8015290"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dapsone crosses the placenta (Brabin 2004).</p>
<p style="text-indent:0em;margin-top:2em;">Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Dapsone may displace bound bilirubin in the neonate, increasing the risk of kernicterus. In addition, there are case reports of hemolytic anemia in fetus/infant following maternal treatment. Neonatal care providers should be informed if dapsone is used near delivery (HHS [OI adult 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Dapsone may be used in pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis. Dapsone may be used as an alternative agent for management of <i>Pneumocystis jirovecii</i> pneumonia (PCP) or <i>Toxoplasma gondii</i> encephalitis in pregnant, patients living with HIV (HHS [OI Adult 2019]).</p></div>
<div class="block mopp drugH1Div" id="F53570457"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (weekly for the first month, monthly for 6 months, then semiannually), reticulocyte count, and liver function tests; check G-6-PD levels prior to initiation of dapsone; monitor for signs of jaundice, hemolysis, or methemoglobinemia. </p></div>
<div class="block pha drugH1Div" id="F8015309"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive antagonist of para-aminobenzoic acid (PABA) and prevents normal bacterial utilization of PABA for the synthesis of folic acid</p></div>
<div class="block phk drugH1Div" id="F8015311"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and almost complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Dapsone: 70% to 90%; Metabolite: ~99% (Zuidema 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1.5 L/kg (Zuidema 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (acetylation and hydroxylation); forms multiple metabolites (Zuidema 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children: 15.1 hours (Mirochnick 1993); Adults: 28 hours (range: 10 to 50 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~85%, mainly as metabolites [5 to 15% unchanged (Zuidema 1986)]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390227"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Daps | Dapsona Lazar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lepsone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Furp dapsona</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dapsulon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dapson Fatol | Dapson tillomed</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Dapson Scanpharm</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dapsona Lazar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dapson Fatol | Dapson Scanpharm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sulfona</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dapsone cox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dapson mae</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dds</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lectisol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Novopon | Taiguk dapsone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon | Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon | Dapson | Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dapsoderm-x | Dapsone nos | Novasulfon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ccm dapsone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dapson | Dapson mae | Dapson ratiopharm | Dapson Tiofarma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dapson | Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lepravir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dermosone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon | Dapson</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dapsona | Sulfona</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dapson | Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dapson | Dapson Fatol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon | Dopsan | Servidapsone</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Avlosulfon | Servidapsone | X Dapsone</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agodaps | Lapsone</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Medi dapsone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16639690">
<a name="16639690"></a>Abidi MH, Kozlowski JR, Ibrahim RB, Peres E. The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. <i>Hematol Oncol</i>. 2006;24(3):164-5. doi:10.1002/hon.780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16639690/pubmed" id="16639690" target="_blank">16639690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35464541">
<a name="35464541"></a>Abdur Raheem J, Unnisa A, Iqubal M. Dapsone as a detrimental cause of necrotizing fasciitis with severe resistant neutropenia: <i>A Case Report</i>. <i>Cureus</i>. 2022;14(3):e23076. doi:10.7759/cureus.23076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/35464541/pubmed" id="35464541" target="_blank">35464541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422237">
<a name="21422237"></a>Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA. Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity. <i>J Clin Pharmacol</i>. 2012;52(2):272-278. doi:10.1177/0091270010393343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/21422237/pubmed" id="21422237" target="_blank">21422237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aczone.2012.02">
<a name="Aczone.2012.02"></a>Aczone prescribing information, Allergan, Inc, Irvine CA, February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16361748">
<a name="16361748"></a>Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review.<i> J Dermatol</i>. 2005;32(11):883-889. doi:10.1111/j.1346-8138.2005.tb00865.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16361748/pubmed" id="16361748" target="_blank">16361748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470834">
<a name="17470834"></a>Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. <i>Ann Intern Med</i>. 2007;146(9):657-665. doi:10.7326/0003-4819-146-9-200705010-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/17470834/pubmed" id="17470834" target="_blank">17470834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25999753">
<a name="25999753"></a>Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. <i>Clin Cosmet Investig Dermatol</i>. 2015;8:257-265. doi:10.2147/CCID.S69127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25999753/pubmed" id="25999753" target="_blank">25999753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15342970">
<a name="15342970"></a>Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. <i>Medicine (Baltimore)</i>. 2004;83(5):265-273. doi:10.1097/01.md.0000141096.00377.3f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15342970/pubmed" id="15342970" target="_blank">15342970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23285328">
<a name="23285328"></a>Azizi A, Lawaf S. The management of oral pemphigus vulgaris with systemic corticosteroids and dapsone. <i>J Dent Res Dent Clin Dent Prospects</i>. 2008;2(1):33-37. doi:10.5681/joddd.2008.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/23285328/pubmed" id="23285328" target="_blank">23285328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21852596">
<a name="21852596"></a>Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. <i>Ann Pharmacother</i>. 2011;45(9):1103-1115. doi:10.1345/aph.1Q139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/21852596/pubmed" id="21852596" target="_blank">21852596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8170736">
<a name="8170736"></a>Barnett ED, Pelton SI, Mirochnick M, Cooper ER. Dapsone for prevention of <i>Pneumocystis pneumonia</i> in children with acquired immunodeficiency syndrome. <i>Pediatr Infect Dis J</i>. 1994;13(1):72-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8170736/pubmed" id="8170736" target="_blank">8170736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32140985">
<a name="32140985"></a>Bartakke SP, Sampagar AA, Reddy NA, Kangle R. Dapsone induced agranulocytosis and hemolytic anemia in immune thrombocytopenic purpura. <i>Indian J Pediatr</i>. 2020;87(10):856. doi:10.1007/s12098-020-03226-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32140985/pubmed" id="32140985" target="_blank">32140985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29305344">
<a name="29305344"></a>Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. <i>Am J Health Syst Pharm</i>. 2018;75(3):97-104. doi:10.2146/ajhp160961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/29305344/pubmed" id="29305344" target="_blank">29305344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8678080">
<a name="8678080"></a>Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as <i>Pneumocystis carinii</i> pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. <i>Am J Med</i>. 1996;100(6):611-616. doi:10.1016/s0002-9343(96)00008-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8678080/pubmed" id="8678080" target="_blank">8678080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766904">
<a name="35766904"></a>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2022;36(10):1689-1704. doi:10.1111/jdv.18220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/35766904/pubmed" id="35766904" target="_blank">35766904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15870135">
<a name="15870135"></a>Borrás-Blasco J, Conesa-García V, Navarro-Ruiz A, Devesa P, Matarredona J, Marín-Jiménez F. Pure red cell aplasia associated with dapsone therapy. <i>Ann Pharmacother</i>. 2005;39(6):1137-1138. doi:10.1345/aph.1E349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15870135/pubmed" id="15870135" target="_blank">15870135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15230645">
<a name="15230645"></a>Brabin BJ, Eggelte TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. <i>Drug Saf</i>. 2004;27(9):633-648. doi:10.2165/00002018-200427090-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15230645/pubmed" id="15230645" target="_blank">15230645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29512326">
<a name="29512326"></a>Cai F, Lucas M, Yun J. Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. <i>Intern Med J</i>. 2018;48(3):363-364. doi:10.1111/imj.13730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/29512326/pubmed" id="29512326" target="_blank">29512326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18037117">
<a name="18037117"></a>Callen JP, Jackson JM. Pyoderma gangrenosum: an update. <i>Rheum Dis Clin North Am</i>. 2007;33(4):787-802. doi:10.1016/j.rdc.2007.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/18037117/pubmed" id="18037117" target="_blank">18037117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7973902">
<a name="7973902"></a>Chalasani P, Baffoe-Bonnie H, Jurado RL. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. <i>South Med J</i>. 1994;87(11):1145114-6. doi:10.1097/00007611-199411000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/7973902/pubmed" id="7973902" target="_blank">7973902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20713773">
<a name="20713773"></a>Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.<i> Arch Dermatol</i>. 2010;146(12):1373-1379. doi:10.1001/archdermatol.2010.198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/20713773/pubmed" id="20713773" target="_blank">20713773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11311458">
<a name="11311458"></a>Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. <i>Toxicology</i>. 2001;162(1):53-60. doi:10.1016/s0300-483x(01)00360-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/11311458/pubmed" id="11311458" target="_blank">11311458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25358414">
<a name="25358414"></a>Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. <i>Am J Clin Dermatol</i>. 2014;15(6):517-524. doi:10.1007/s40257-014-0098-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25358414/pubmed" id="25358414" target="_blank">25358414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-449538">
<a name="449538"></a>Damiani JM, Levine HL. Relapsing polychondritis—report of ten cases. <i>Laryngoscope.</i> 1979;89:929-946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/449538/pubmed" id="449538" target="_blank">449538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16146539">
<a name="16146539"></a>Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients. <i>Eur J Haematol</i>. 2005;75(4):328-331. doi:10.1111/j.1600-0609.2005.00545.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16146539/pubmed" id="16146539" target="_blank">16146539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dapsone.2016.02">
<a name="Dapsone.2016.02"></a>Dapsone tablets, USP [prescribing information]. East Brunswick, NJ: Rising Pharmaceuticals Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25097293">
<a name="25097293"></a>Das AK, Jawed Q. Drug-induced acute pancreatitis: a rare manifestation of an incomplete "dapsone syndrome". <i>Indian J Pharmacol</i>. 2014;46(4):455-457. doi:10.4103/0253-7613.135967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25097293/pubmed" id="25097293" target="_blank">25097293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28552804">
<a name="28552804"></a>Devarbhavi H, Raj S, Joseph T, Singh R, Patil M. Features and treatment of dapsone-induced hepatitis, based on analysis of 44 cases and literature review. <i>Clin Gastroenterol Hepatol</i>. 2017;15(11):1805-1807. doi:10.1016/j.cgh.2017.05.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/28552804/pubmed" id="28552804" target="_blank">28552804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29222960">
<a name="29222960"></a>Devarbhavi H, Patil M, Reddy VV, Singh R, Joseph T, Ganga D. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. <i>Liver Int</i>. 2018;38(7):1322-1329. doi:10.1111/liv.13662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/29222960/pubmed" id="29222960" target="_blank">29222960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34427944">
<a name="34427944"></a>Devarbhavi H, Patil M, Menon M. Association of human leukocyte antigen-B*13:01 with dapsone-induced liver injury. <i>Br J Clin Pharmacol</i>. 2022;88(3):1369-1372. doi:10.1111/bcp.15054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/34427944/pubmed" id="34427944" target="_blank">34427944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30365585">
<a name="30365585"></a>Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. <i>J Drugs Dermatol</i>. 2018;17(10):1058-1060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/30365585/pubmed" id="30365585" target="_blank">30365585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21666744">
<a name="21666744"></a>Dunyo S, Sirugo G, Sesay S, et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. <i>PLoS One</i>. 2011;6(6):e17371. doi:10.1371/journal.pone.0017371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/21666744/pubmed" id="21666744" target="_blank">21666744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9862944">
<a name="9862944"></a>El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. <i>N Engl J Med</i>. 1998;339(26):1889-1895. doi:10.1056/NEJM199812243392604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/9862944/pubmed" id="9862944" target="_blank">9862944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3722506">
<a name="3722506"></a>Ermacora E, Prampolini L, Tribbia G, et.al. Long-term follow-up of dermatitis herpetiformis in children. <i>J Am Acad Dermatol.</i> 1986;15(1):24-30. doi:10.1016/s0190-9622(86)70137-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/3722506/pubmed" id="3722506" target="_blank">3722506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21246536">
<a name="21246536"></a>Esbenshade AJ, Ho RH, Shintani A, Zhao Z, Smith LA, Friedman DL. Dapsone-induced methemoglobinemia: a dose-related occurrence? <i>Cancer</i>. 2011;117(15):3485-3492. doi:10.1002/cncr.25904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/21246536/pubmed" id="21246536" target="_blank">21246536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31631707">
<a name="31631707"></a>Ezhilarasan D. Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia. <i>Drug Chem Toxicol</i>. 2021;44(3):330-333. doi:10.1080/01480545.2019.1679829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31631707/pubmed" id="31631707" target="_blank">31631707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12814335">
<a name="12814335"></a>Fabbri P, Cardinali C, Giomi B, et al. Cutaneous lupus erythematosus: diagnosis and management. <i>Am J Clin Dermatol</i>. 2003;4(7):449-465. doi:10.2165/00128071-200304070-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12814335/pubmed" id="12814335" target="_blank">12814335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19112496">
<a name="19112496"></a>Fanello CI, Karema C, Avellino P, et al. High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. <i>PLoS One</i>. 2008;3(12):e4031. doi:10.1371/journal.pone.0004031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19112496/pubmed" id="19112496" target="_blank">19112496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31198424">
<a name="31198424"></a>Fernando M, Kankananarachchi I, Navabalasooriyar P, Herath B, Punchihewa P. A case of dapsone-induced severe agranulocytosis causing life-threatening skin sepsis in a Sri Lankan child with borderline leprosy: A success story! <i>Case Rep Med</i>. 2019;2019:2314379. doi:10.1155/2019/2314379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31198424/pubmed" id="31198424" target="_blank">31198424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22137225">
<a name="22137225"></a>Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. <i>Clin Dermatol</i>. 2012;30(1):38-50. doi:10.1016/j.clindermatol.2011.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22137225/pubmed" id="22137225" target="_blank">22137225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25156688">
<a name="25156688"></a>Garcia A, Yi NJ, Lee KB, et al. Fulminant hepatitis linked to dapsone hypersensitivity syndrome requiring urgent living donor liver transplantation: a case report. <i>Pediatr Transplant</i>. 2014;18(7):E240-E245. doi:10.1111/petr.12343. Erratum in: <i>Pediatr Transplant</i>. 2018;22(5):e13224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25156688/pubmed" id="25156688" target="_blank">25156688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15183590">
<a name="15183590"></a>Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis.<i> Int J Pediatr Otorhinolaryngol</i>. 2004;68(7):965-970. doi:10.1016/j.ijporl.2004.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15183590/pubmed" id="15183590" target="_blank">15183590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9163598">
<a name="9163598"></a>Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. <i>Br J Haematol</i>. 1997;97(2):336-339. doi:10.1046/j.1365-2141.1997.412687.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/9163598/pubmed" id="9163598" target="_blank">9163598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721106">
<a name="28721106"></a>Guragain S, Upadhayay N, Bhattarai BM. Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study. <i>Clin Pharmacol</i>. 2017;9:73-78. doi:10.2147/CPAA.S135846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/28721106/pubmed" id="28721106" target="_blank">28721106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19824739">
<a name="19824739"></a>Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. <i>Am J Clin Dermatol</i>. 2009;10(6):383-96. doi:10.2165/11310740-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19824739/pubmed" id="19824739" target="_blank">19824739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35176506">
<a name="35176506"></a>Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. <i>J Allergy Clin Immunol Pract</i>. 2022;10(5):1155-1167.e5. doi:10.1016/j.jaip.2022.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/35176506/pubmed" id="35176506" target="_blank">35176506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HRSA.2021">
<a name="HRSA.2021"></a>Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. Updated April 2018. Accessed June 8, 2021. <a href="https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html" target="_blank">https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4969972">
<a name="4969972"></a>Hocking DR. Neonatal haemolytic disease due to dapsone. <i>Med J Aust</i>. 1968;1(26):1130-1131. doi:10.5694/j.1326-5377.1968.tb29209.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/4969972/pubmed" id="4969972" target="_blank">4969972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9692656">
<a name="9692656"></a>Holtzer CD, Flaherty JF Jr, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. <i>Pharmacotherapy</i>. 1998;18(4):831-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/9692656/pubmed" id="9692656" target="_blank">9692656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2360840">
<a name="2360840"></a>Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. <i>Arch Dermatol</i>. 1990;126(7):919-22. doi:10.1001/archderm.1990.01670310081011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/2360840/pubmed" id="2360840" target="_blank">2360840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32691244">
<a name="32691244"></a>Hsieh CY, Tsai TF. Drug-induced neutropenia during treatment of non-neoplastic dermatologic diseases: A review. <i>Clin Drug Investig</i>. 2020;40(10):915-926. doi:10.1007/s40261-020-00956-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32691244/pubmed" id="32691244" target="_blank">32691244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10216653">
<a name="10216653"></a>Kabra NS, Nanavati RN, Srinivasan G. Neonatal methemoglobinemia due to transplacental transfer of dapsone. <i>Indian Pediatr</i>. 1998;35(6):553-555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/10216653/pubmed" id="10216653" target="_blank">10216653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32961314">
<a name="32961314"></a>Kang DY, Yun J, Lee SY, et al; Korean severe cutaneous adverse reactions consortium. A nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea. <i>J Allergy Clin Immunol Pract</i>. 2021;9(2):929-936.e7. doi:10.1016/j.jaip.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32961314/pubmed" id="32961314" target="_blank">32961314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18811870">
<a name="18811870"></a>Kar BR. Dapsone-induced photosensitivity: a rare clinical presentation. <i>Photodermatol Photoimmunol Photomed</i>. 2008;24(5):270-271. doi:10.1111/j.1600-0781.2008.00372.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/18811870/pubmed" id="18811870" target="_blank">18811870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32714715">
<a name="32714715"></a>Keerty D, Eaton K, Haynes E. Dapsone-induced hypoxia. <i>Cureus</i>. 2020;12(7):e9334. doi:10.7759/cureus.9334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32714715/pubmed" id="32714715" target="_blank">32714715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19250401">
<a name="19250401"></a>Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. <i>Pediatric Dermatology</i>. 2009;26(1):28-33. doi:10.1111/j.1525-1470.2008.00817.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19250401/pubmed" id="19250401" target="_blank">19250401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32947344">
<a name="32947344"></a>Khatri A, Lal M R S, Bhaskaran MC. Dapsone-associated hemolytic anemia in renal transplant recipients with normal glucose-6-phosphate-dehydrogenase levels. <i>Am J Ther</i>. 2022;29(3):e369-e372. doi:10.1097/MJT.0000000000001252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32947344/pubmed" id="32947344" target="_blank">32947344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832951">
<a name="25832951"></a>Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid. <i>Intern Med</i>. 2015;54(7):827-831. doi:10.2169/internalmedicine.54.3406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25832951/pubmed" id="25832951" target="_blank">25832951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15244240">
<a name="15244240"></a>Kishida Y, Kameyama J, Nei M, Hashimoto T, Baba K. Linear IgA bullous dermatosis of neonatal onset: case report and review of the literature. <i>Acta Paediatr</i>. 2004;93(6):850-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15244240/pubmed" id="15244240" target="_blank">15244240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2011">
<a name="Kliegman.2011"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics.</i> 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2016">
<a name="Kliegman.2016"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16756657">
<a name="16756657"></a>Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The dapsone hypersensitivity syndrome revisited: A potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. <i>J Occup Med Toxicol</i>. 2006;1:9. doi:10.1186/1745-6673-1-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16756657/pubmed" id="16756657" target="_blank">16756657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22370290">
<a name="22370290"></a>Lai YC, Wang CS, Wang YC, Hsu YL, Chuang LM. Falsely decreased HbA1c in a type 2 diabetic patient treated with dapsone. <i>J Formos Med Assoc</i>. 2012;111(2):109-112. doi:10.1016/j.jfma.2012.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22370290/pubmed" id="22370290" target="_blank">22370290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16212642">
<a name="16212642"></a>Lee I, Barton TD, Goral S, et al. Complications related to dapsone use for <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in solid organ transplant recipients. <i>Am J Transplant</i>. 2005;5(11):2791-2795. doi:10.1111/j.1600-6143.2005.01079.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16212642/pubmed" id="16212642" target="_blank">16212642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25628986">
<a name="25628986"></a>Lee SM, Geetha D. Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. <i>Springerplus</i>. 2015;4:29. doi:10.1186/s40064-015-0816-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/25628986/pubmed" id="25628986" target="_blank">25628986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22392826">
<a name="22392826"></a>Legendre DP, Muzny CA, Swiatlo E. Hansen’s disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions.<i> Pharmacotherapy.</i> 2012;32(1):27-37. doi:10.1002/PHAR.1009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22392826/pubmed" id="22392826" target="_blank">22392826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12077711">
<a name="12077711"></a>Letko E, Zafirakis P, Baltatzis S, Voudouri A, Livir-Rallatos C, Foster CS. Relapsing polychondritis: a clinical review. <i>Semin Arthritis Rheum</i>. 2002;31(6):384-395. doi:10.1053/sarh.2002.32586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12077711/pubmed" id="12077711" target="_blank">12077711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916737">
<a name="30916737"></a>Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. <i>JAMA Dermatol</i>. 2019;155(6):666-672. doi:10.1001/jamadermatol.2018.5360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/30916737/pubmed" id="30916737" target="_blank">30916737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22307940">
<a name="22307940"></a>Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. <i>Acta Derm Venereol</i>. 2012;92(2):194-199. doi:10.2340/00015555-1268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22307940/pubmed" id="22307940" target="_blank">22307940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19289756">
<a name="19289756"></a>Lynde CB, Bruce AJ, Rogers RS 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol. 2009;145(3):273-276. doi:10.1001/archdermatol.2008.591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19289756/pubmed" id="19289756" target="_blank">19289756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33417185">
<a name="33417185"></a>Mannemuddhu SS, Ali R, Kadhem S, Ruchi R. Unusual cause of persistent dyspnea in a patient with nephrotic syndrome: Dapsone-induced methemoglobinemia. <i>CEN Case Rep</i>. 2021;10(3):336-340. doi:10.1007/s13730-020-00565-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/33417185/pubmed" id="33417185" target="_blank">33417185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mar-Dapsone.2018.09">
<a name="Mar-Dapsone.2018.09"></a>Mar-Dapsone (dapsone) [product monograph]. Ottawa, Ontario, Canada: Marcan Pharmaceuticals, Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034550">
<a name="28034550"></a>May SM, Motosue MS, Park MA. Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):831-833. doi:10.1016/j.jaip.2016.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/28034550/pubmed" id="28034550" target="_blank">28034550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2392131">
<a name="2392131"></a>Medina I, Mills J, Leoung G, et al. Oral therapy for <i>Pneumocystis carinii</i> pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. <i>N Engl J Med</i>. 1990;323(12):776-782. doi:10.1056/NEJM199009203231202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/2392131/pubmed" id="2392131" target="_blank">2392131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12571474">
<a name="12571474"></a>Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB. Dapsone therapy for children with immune thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2003;25(2):173-175. doi:10.1097/00043426-200302000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12571474/pubmed" id="12571474" target="_blank">12571474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7967777">
<a name="7967777"></a>Meyerson MA, Cohen PR. Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus. <i>Mayo Clin Proc</i>. 1994;69(12):1159-1162. doi:10.1016/s0025-6196(12)65768-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/7967777/pubmed" id="7967777" target="_blank">7967777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19330244">
<a name="19330244"></a>Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. <i>Clinics (Sao Paulo)</i>. 2009;64(3):193-198. doi:10.1590/s1807-59322009000300008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19330244/pubmed" id="19330244" target="_blank">19330244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8496767">
<a name="8496767"></a>Mirochnick M, Michaels M, Clarke D, Breña A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. <i>J Pediatr</i>. 1993;122(5 pt 1):806-809. doi:10.1016/s0022-3476(06)80033-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8496767/pubmed" id="8496767" target="_blank">8496767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24215452">
<a name="24215452"></a>Mitsides N, Green D, Middleton R, et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. <i>Transpl Infect Dis</i>. 2014;16(1):37-43. doi:10.1111/tid.12161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/24215452/pubmed" id="24215452" target="_blank">24215452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27230975">
<a name="27230975"></a>Murphy AG, Grossman SA. Acute hemolysis in a patient with a newly diagnosed glioblastoma. <i>CNS Oncol</i>. 2016;5(3):125-129. doi:10.2217/cns-2015-0009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/27230975/pubmed" id="27230975" target="_blank">27230975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18971091">
<a name="18971091"></a>Naik PM, Lyon GM 3rd, Ramirez A, et al. Dapsone-induced hemolytic anemia in lung allograft recipients. <i>J Heart Lung Transplant</i>. 2008;27(11):1198-202. doi:10.1016/j.healun.2008.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/18971091/pubmed" id="18971091" target="_blank">18971091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management (CG183). 2014; clinical guideline 183. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20631737">
<a name="20631737"></a>Nessim SJ, Lipman ML. The case/cyanosis in a hemodialysis patient. <i>Kidney Int.</i> 2010;78(3):327-328. doi:10.1038/ki.2010.152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/20631737/pubmed" id="20631737" target="_blank">20631737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5437633">
<a name="5437633"></a>Ognibene AJ. Agranulocytosis due to dapsone. <i>Ann Intern Med</i>. 1970;72(4):521-524. doi:10.7326/0003-4819-72-4-521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/5437633/pubmed" id="5437633" target="_blank">5437633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21478917">
<a name="21478917"></a>Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. <i>Bone Marrow Transplant</i>. 2012;47(3):399-403. doi:10.1038/bmt.2011.83<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/21478917/pubmed" id="21478917" target="_blank">21478917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29515281">
<a name="29515281"></a>Pai S, Munshi R, Nayak C. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus. <i>Indian J Pharmacol</i>. 2017;49(5):396-398. doi:10.4103/ijp.IJP_764_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/29515281/pubmed" id="29515281" target="_blank">29515281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22993389">
<a name="22993389"></a>Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. <i>Blood</i>. 2012;120(20):4123-4133. doi:10.1182/blood-2012-03-416032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22993389/pubmed" id="22993389" target="_blank">22993389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32700588">
<a name="32700588"></a>Park HJ, Park JW, Kim SH, et al; Allergy Work Group of KAAACI. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. <i>Expert Opin Drug Saf</i>. 2020;19(10):1349-1356. doi:10.1080/14740338.2020.1796965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32700588/pubmed" id="32700588" target="_blank">32700588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8038322">
<a name="8038322"></a>Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. <i>Clin Infect Dis</i>. 1994;18(4):630-632. doi:10.1093/clinids/18.4.630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8038322/pubmed" id="8038322" target="_blank">8038322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26599634">
<a name="26599634"></a>Poirot E, Vittinghoff E, Ishengoma D, et al. Risks of hemolysis in glucose-6-phosphate dehydrogenase deficient infants exposed to chlorproguanil-dapsone, mefloquine and sulfadoxine-pyrimethamine as part of intermittent presumptive treatment of malaria in infants. <i>PLoS One</i>. 2015;10(11):e0142414. doi:10.1371/journal.pone.0142414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/26599634/pubmed" id="26599634" target="_blank">26599634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31166407">
<a name="31166407"></a>Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. <i>An Bras Dermatol</i>. 2019;94(suppl 1):20-32. doi:10.1590/abd1806-4841.2019940206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31166407/pubmed" id="31166407" target="_blank">31166407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19846889">
<a name="19846889"></a>Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186. doi:10.1182/blood-2009-06-225565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19846889/pubmed" id="19846889" target="_blank">19846889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32753123">
<a name="32753123"></a>Rassner M, Jung J, Schneider J, Wäsch R, Engelhardt M. Dapsone-induced hemolytic anemia in multiple myeloma: Case report of various differential diagnoses. <i>Clin Lymphoma Myeloma Leuk</i>. 2020;20(11):e821-e825. doi:10.1016/j.clml.2020.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32753123/pubmed" id="32753123" target="_blank">32753123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6742871">
<a name="6742871"></a>Reunala T, Kosnai I, Karpati S, Kuitunen P, Török E, Savilahti E. Dermatitis herpetiformis: jejunal findings and skin response to gluten free diet. <i>Arch Dis Child</i>. 1984;59(6):517-522. doi:10.1136/adc.59.6.517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/6742871/pubmed" id="6742871" target="_blank">6742871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-760656">
<a name="760656"></a>Ridgway HB, Hansotia PL, Schorr WF. Relapsing polychondritis: unusual neurological findings and therapeutic efficacy of dapsone. <i>Arch Dermatology.</i> 1979;115(1):43. doi:10.1001/archderm.115.1.43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/760656 /pubmed" id="760656 " target="_blank">760656 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32047930">
<a name="32047930"></a>Rogers LR, Oppelt P, Nayak L. Hemolytic anemia associated with dapsone PCP prophylaxis in GBM patients with normal G6PD activity. <i>Neuro Oncol</i>. 2020;22(6):892-893. doi:10.1093/neuonc/noaa026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/32047930/pubmed" id="32047930" target="_blank">32047930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037880">
<a name="7037880"></a>Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. <i>J Am Acad Dermatol</i>. 1982;6(2):215-223. doi:10.1016/s0190-9622(82)70014-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/7037880/pubmed" id="7037880" target="_blank">7037880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093998">
<a name="31093998"></a>Salmi TT. Dermatitis herpetiformis. <i>Clin Exp Dermatol</i>. 2019;44(7):728-731. doi:10.1111/ced.13992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/31093998/pubmed" id="31093998" target="_blank">31093998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7065565">
<a name="7065565"></a>Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE. Hemolytic anemia induced by dapsone transmitted through breast milk. <i>Ann Intern Med</i>. 1982;96(4):465-466. doi:10.7326/0003-4819-96-4-465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/7065565/pubmed" id="7065565" target="_blank">7065565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34017337">
<a name="34017337"></a>Satapornpong P, Pratoomwun J, Rerknimitr P, et al. <i>HLA-B*13 :01</i> is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients. <i>Front Immunol</i>. 2021;12:661135. doi:10.3389/fimmu.2021.661135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/34017337/pubmed" id="34017337" target="_blank">34017337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120067">
<a name="26120067"></a>Sauvetre G, MahÉvas M, Limal N, et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. <i>Am J Hematol</i>. 2015;90(10):E201-E202. doi:10.1002/ajh.24068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/26120067/pubmed" id="26120067" target="_blank">26120067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11844995">
<a name="11844995"></a>Schrier SL. Pathophysiology of thalassemia. <i>Curr Opin Hematol</i>. 2002;9(2):123-126. doi:10.1097/00062752-200203000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/11844995/pubmed" id="11844995" target="_blank">11844995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi: 10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12453003">
<a name="12453003"></a>Serwin AB, Myśliwiec H, Laudańska H, Chodynicka B. Linear IgA bullous dermatosis in a diabetic patient with chronic renal failure. <i>Int J Dermatol</i>. 2002;41(11):778-780. doi:10.1046/j.1365-4362.2002.01620_1.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12453003/pubmed" id="12453003" target="_blank">12453003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35371634">
<a name="35371634"></a>Shenouda M, Padilla M, Silva J, Castillo H, Austin A. Dapsone-induced methemoglobinemia: A case report. <i>Cureus</i>. 2022;14(2):e22466. doi:10.7759/cureus.22466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/35371634/pubmed" id="35371634" target="_blank">35371634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8414776">
<a name="8414776"></a>Stavola JJ, Noel GJ. Efficacy and safety of dapsone prophylaxis against <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus-infected children. <i>Pediatr Infect Dis J</i>. 1993;12(8):644-647. doi:10.1097/00006454-199308000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8414776/pubmed" id="8414776" target="_blank">8414776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33270224">
<a name="33270224"></a>St Claire K, Kaul S, Caldito EG, Kramer ON, Griffin T, Albrecht J. Dapsone-induced agranulocytosis: symptoms may alert more reliably than the current blood monitoring protocol. <i>Br J Dermatol</i>. 2021;184(5):962-963. doi:10.1111/bjd.19708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/33270224/pubmed" id="33270224" target="_blank">33270224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28494097">
<a name="28494097"></a>Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.<i> Br J Dermatol.</i> 2017;177(5):1299-1305. doi:10.1111/bjd.15649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/28494097/pubmed" id="28494097" target="_blank">28494097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tan.1">
<a name="Tan.1"></a>Tan YS, Rajahram GS. The blue man: A case of dapsone-induced methaemoglobinaemia. <i>International Journal of Infectious Diseases</i>. 2020; 101(suppl 1): 161-162. doi: 10.1016/j.ijid.2020.09.436</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29541744">
<a name="29541744"></a>Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: A systematic review and meta-analysis. <i>JAMA Dermatol</i>. 2018;154(4):441-446. doi:10.1001/jamadermatol.2017.6484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/29541744/pubmed" id="29541744" target="_blank">29541744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17251816">
<a name="17251816"></a>Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. <i>Cornea</i>. 2007;26(2):215-219. doi:10.1097/ICO.0b013e31802eb078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/17251816/pubmed" id="17251816" target="_blank">17251816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28885988">
<a name="28885988"></a>Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. <i>Pharmacogenet Genomics</i>. 2017;27(12):429-437. doi:10.1097/FPC.0000000000000306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/28885988/pubmed" id="28885988" target="_blank">28885988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12954953">
<a name="12954953"></a>Thappa DM, Jeevankumar B. Chronic bullous dermatosis of childhood. <i>Postgrad Med J</i>. 2003;79(934):437. doi:10.1136/pmj.79.934.437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12954953/pubmed" id="12954953" target="_blank">12954953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2717998">
<a name="2717998"></a>Thornton YS, Bowe ET. Neonatal hyperbilirubinemia after treatment of maternal leprosy. <i>South Med J</i>. 1989;82(5):668. doi:10.1097/00007611-198905000-00037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/2717998/pubmed" id="2717998" target="_blank">2717998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15:1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3129552">
<a name="3129552"></a>Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. <i>J Pharmacol Exp Ther</i>. 1988;245(1):274-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/3129552/pubmed" id="3129552" target="_blank">3129552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30030892">
<a name="30030892"></a>Urbancic KF, Pisasale D, Wight J, Trubiano JA. Dapsone safety in hematology patients: Pathways to optimizing <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in hematology malignancy and transplant recipients. <i>Transpl Infect Dis</i>. 2018;20(6):e12968. doi:10.1111/tid.12968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/30030892/pubmed" id="30030892" target="_blank">30030892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.1">
<a name="USHHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Updated October 2015. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2">
<a name="USHHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed April 30, 2020. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24026795">
<a name="24026795"></a>Vas A, Laws P, Marsland A, McQuillan O. Acute generalised exanthematous pustulosis induced by <i>Pneumocystis jirovecii</i> pneumonia prophylaxis with dapsone. <i>Int J STD AIDS</i>. 2013;24(9):745-747. doi:10.1177/0956462413482813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/24026795/pubmed" id="24026795" target="_blank">24026795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15204146">
<a name="15204146"></a>Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. <i>J Dermatolog Treat</i>. 2004;15(3):146-152. doi:10.1080/09546630410031909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15204146/pubmed" id="15204146" target="_blank">15204146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6322702">
<a name="6322702"></a>Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy. Case report and review. <i>Arch Dermatol</i>. 1984;120(3):356-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/6322702/pubmed" id="6322702" target="_blank">6322702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9606476">
<a name="9606476"></a>Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. <i>Ann Pharmacother</i>. 1998;32(5):549-553. doi:10.1345/aph.17003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/9606476/pubmed" id="9606476" target="_blank">9606476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22970604">
<a name="22970604"></a>World Health Organization. WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61, 1 p following 61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/22970604/pubmed" id="22970604" target="_blank">22970604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18209165">
<a name="18209165"></a>Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. <i>Arch Dermatol</i>. 2008;144(1):25-32. doi:10.1001/archderm.144.1.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/18209165/pubmed" id="18209165" target="_blank">18209165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15390276">
<a name="15390276"></a>Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for <i>Pneumocystis carinii</i> pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. <i>Pediatr Blood Cancer</i>. 2005;44(1):55-62. doi:10.1002/pbc.20164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15390276/pubmed" id="15390276" target="_blank">15390276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Global Leprosy Strategy 2016-2020: Accelerating towards a leprosy-free world. August 2016. http://www.who.int/lep/resources/9789290225096/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for the diagnosis, treatment and prevention of leprosy. Published 2018. Accessed April 19, 2021. https://apps.who.int/iris/handle/10665/274127.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3530584">
<a name="3530584"></a>Zuidema J, Hilbers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. <i>Clin Pharmacokinet</i>. 1986;11(4):299-315. doi: 0.2165/00003088-198611040-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/3530584/pubmed" id="3530584" target="_blank">3530584</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15963 Version 315.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
